LMA vs High-flow Nasal Oxygen During ECT in Obese Patients
Launched by EULJI UNIVERSITY HOSPITAL · Jul 23, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different ways to help people breathe during electroconvulsive therapy (ECT), a treatment often used for certain mental health conditions. Specifically, it compares the use of a laryngeal mask airway (LMA)—a soft tube placed in the throat—with high-flow nasal oxygen (HFNC), which delivers oxygen through special tubes in the nose. The study focuses on adults who are obese (with a body mass index of 30 or higher), because these patients have a higher chance of experiencing low oxygen levels during ECT when they are under anesthesia.
If you are an adult with obesity and are scheduled to have at least four ECT sessions, you might be eligible to join this study. During the trial, each person will receive both breathing support methods in alternating order over four ECT treatments. Doctors and nurses will closely watch oxygen levels, breathing, vital signs, and any confusion or discomfort after the procedure. This helps the medical team understand which method is safer and works better for obese patients receiving ECT. If you are interested, your healthcare team will explain the study in detail and answer any questions before you decide to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Patients scheduled to undergo ≥ 4 electroconvulsive therapy (ECT) sessions
- • Body mass index (BMI) ≥ 30 kg/m² (WHO obesity classification)
- • American Society of Anesthesiologists (ASA) physical status class I to III
- • Provided written informed consent (by patient or legal guardian)
- Exclusion Criteria:
- • Patients under 18 years of age
- • Patients with ASA class IV or V
- • Patients with anticipated dental injury risk that precludes use of a laryngeal mask airway
- • Patients or guardians who refuse participation
About Eulji University Hospital
Eulji University Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. As a prominent academic hospital in South Korea, it combines cutting-edge medical technology with a strong emphasis on education and training for healthcare professionals. Eulji University Hospital fosters collaboration among multidisciplinary teams to conduct high-quality research across various therapeutic areas, ensuring adherence to rigorous ethical standards and regulatory compliance. By prioritizing patient safety and scientific integrity, the hospital plays a vital role in contributing to the development of new treatments and enhancing the overall healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported